1. Morgan JP. Phenylpropanolamine: a critical analysis of reported adverse reactions and overdosage. 1st ed. Fort Lee (NJ): Jack K Burgess, Inc., 1986
2. U.S. Department of Health & Human Services, U.S. Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Reviewer guidance: conducting a clinical safety review of a new product application and preparing a report on the review [online]. Available from URL: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072974.pdf [Accessed 2012 Sep 20]
3. Cohen AF. Developing drug prototypes: pharmacology replaces safety and tolerability? Nat Rev Drug Discov 2010 Nov; 9 (11): 856–65
4. Mathieu M. New drug development: a regulatory overview. 8th rev. ed. Waltham (MA): PAREXEL International Corporation, 2008
5. Walker S, McAuslane N, Liberti L, et al. Measuring benefit and balancing risk: strategies for the benefit-risk assessment of new medicines in a risk-averse environment. Clin Pharmacol Ther 2009 Mar; 85 (3): 241–6